DMACDiaMedica Therapeutics Inc.
$8.01+17% 1Y
$8.01
$5.3352 weeks$9.39
Price
+17%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 7% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for DMAC today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$431.6M
1 year+17%
5 years+100%
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 11, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jan 5, 2026On December 19, 2025 DiaMedica Therapeutics Inc. (the “Company”) Sold 1,501,000 common shares to a healthcare institution fund at a purchase price of $8.10 per share in a block transaction under its at-the-market offering program.Other event · Form 8-K
- Dec 18, 2025As previously announced, DiaMedica requested and completed an in-person pre-IND meeting with the FDA for a planned study evaluating DM199 in pre-eclampsia.Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.